Sopra Steria - 2020 Universal registration document

5 2020 CONSOLIDATED FINANCIAL STATEMENTS Notes to the consolidated financial statements

Other cash flows in the consolidated cash flow statement 13.3. Beyond the changes presented in the Change in net financial debt Payments on borrowings mainly concerned payments on the table, the consolidated cash flow statement presented on page medium-term loan and the NEU CP programme (see Note 12.3). 162 was affected by movements related to financing activities.

EQUITY AND EARNINGS PER SHARE NOTE 14

Equity 14.1.

All of the Sopra Steria Group shares held by the parent company or any of its subsidiaries are recognised at their acquisition cost, deducted from consolidated equity. Dividends 14.1.3. On 9 April 2020, the Board of Directors decided to submit a resolution at the General Meeting of 9 June 2020 proposing not to pay a dividend in respect of financial year 2019. This resolution passed at the General Meeting. The dividend paid in financial year 2019 in respect of financial year 2018 was €38.0 million, equating to €1.85 per share. Accumulated translation reserves 14.1.4. In line with the principles described in Note 1.4.2.b, accumulated translation reserves include the gains or losses arising on translation from the functional currencies of the Group’s entities to the presentation currency as well as the currency hedging effects of net investments in foreign operations. Movements are recorded in Other comprehensive income. Accumulated translation reserves also reflect the translation effects of gains or losses on disposals of foreign operations.

The consolidated statement of changes in equity is presented on page 161. Changes in share capital 14.1.1. At 31 December 2020, Sopra Steria Group had a share capital of €20,547,701, the same as at 31 December 2019. It is represented by 20,547,701 fully paid-up shares with a par value of €1 each. Transactions in treasury shares 14.1.2. At 31 December 2020, the value of treasury shares recognised as a deduction from consolidated equity was €36.2 million, consisting of 310,525 shares, including 263,713 shares held by UK trusts falling within the consolidation scope and 46,812 shares acquired by Sopra Steria Group, 5,400 of which were acquired under the liquidity agreement and the rest of which were acquired to make any potential share-based payments. This value also includes €3.5 million relating to the Group’s commitment to acquire shares on the market for its free performance share plans (see Note 5.4.1).

At 31 December 2020, accumulated translation reserves by currency were as follows:

31/12/2020

31/12/2019

26 5244276: 7/ .<97:

Swiss franc

8.0

7.9

Pound sterling Indian rupee Norwegian krone

-80.7

-49.6

-0.4

2.6

-23.6

-18.0

Polish zloty

-0.6

-0.2

Singapore dollar Tunisian dinar

0.1

0.5

-1.9

-1.7 -0.0

US dollar

0.4

Other currencies

-10.2

1.3

)!) ( (& "' ( #" & ' &* ' ((& )( (# ( &#)$

The Other currencies category mainly includes the accumulated translation reserves of associates, and chiefly Axway Software, in the amount of €1.7 million (€8.3 million at 31 December 2019). Non-controlling interests 14.1.5. The contributions to the income statement and balance sheet of entities in which there are non-controlling interests mainly come from joint ventures formed with the UK authorities in the United Kingdom: NHS SBS, 50%-owned by the UK Department of Health, and SSCL, 25%-owned by the Cabinet Office. The Group has 50% and 75% control, respectively. They also relate to the companies in the Galitt group acquired in 2017, as well as Sopra Financial Technology GmbH, acquired in 2019.

The Group has granted the Cabinet Office a put option to sell the shares it holds in SSCL. In the same vein, the Group has entered into an irrevocable commitment to acquire the remaining shares in Galitt, in the form of a put option granted to the other shareholders. Due to the accounting treatment of the put option granted in respect of SSCL and Galitt shares, the amount of non-controlling interests on the balance sheet mainly relates to the UK Department of Health’s share in the net assets of NHS SBS (€29.8 million), and the share of the German banking network Sparda’s cooperative banks in Sopra Financial Technology GmbH (€17.8 million).

216

SOPRA STERIA UNIVERSAL REGISTRATION DOCUMENT 2020